Affiliation: University of Hamburg
- Modern management of children with haemophagocytic lymphohistiocytosisGritta E Janka
Department of Haematology and Oncology, Children's Hospital, University of Hamburg, Hamburg, Germany
Br J Haematol 124:4-14. 2004
- [In vitro drug resistance as independent prognostic factor in the study COALL-O5-92 Treatment of childhood acute lymphoblastic leukemia; two-tiered classification of treatments based on accepted risk criteria and drug sensitivity profiles in study COALL-0G E Janka-Schaub
Abt für Pädiatrische Hämatologie und Onkologie, Universitätskinderklinik Hamburg
Klin Padiatr 211:233-8. 1999..Additional prognostic criteria are therefore urgently needed. In a retrospective Dutch study in childhood ALL drug sensitivity testing with the MTT assay was identified as a new highly significant prognostic factor...
- Hemophagocytic lymphohistiocytosis: when the immune system runs amokG Janka
Pediatric Hematology and Oncology, University Medical Center Hamburg Eppendorf, Hamburg, Germany
Klin Padiatr 221:278-85. 2009..Suppression of the severe hyperinflammation can be achieved with immunosuppressive and immunomodulatory agents and cytostatic drugs. Patients with genetic HLH have to undergo stem cell transplantation for cure...
- Familial and acquired hemophagocytic lymphohistiocytosisG E Janka
Department of Hematology and Oncology, Children s University Hospital, Hamburg, Germany
Annu Rev Med 63:233-46. 2012..Treatment of HLH includes immune-suppressive and immune-modulatory agents, cytostatic drugs, and biological response modifiers. For patients with FHL, stem cell transplantation is indicated and can be curative...
- Hemophagocytic syndromesGritta E Janka
Department of Hematology and Oncology, Children s Hospital, University of Hamburg, Martinistrasse 52, 20246 Hamburg, Germany
Blood Rev 21:245-53. 2007..Awareness of the clinical symptoms and of the diagnostic criteria of HLH is important to start life-saving therapy with immunosuppressive/immunomodulatory agents in time...
- Familial and acquired hemophagocytic lymphohistiocytosisGritta E Janka
Department of Hematology and Oncology, Children s Hospital, University of Hamburg, Hamburg, Germany
Eur J Pediatr 166:95-109. 2007..In conclusion, awareness of the clinical symptoms and of the diagnostic criteria of HLH is crucial in order not to overlook HLH and to start life-saving therapy in time...
- [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase]U zur Stadt
Abt für Pädiatrische Hämatologie und Onkologie, Universitätskinderklinik Eppendorf, Hamburg
Klin Padiatr 212:169-73. 2000..At the end of induction therapy, bone marrow was obtained for cytomorphologic and molecular analysis...
- From neonates to adolescents--the diagnostic significance of pitted erythrocytes in hyposplenic and asplenic childrenK Lehmberg
Department of Paediatric Haematology and Oncology, Children s Hospital, University of Hamburg, Hamburg
Klin Padiatr 219:339-42. 2007..A simple method with reliable reference values is required to determine a patient's splenic function and thereby assess the risk of systemic infection...
- Distribution of cardiac iron measured by magnetic resonance imaging (MRI)-R*2Jin Yamamura
University Medical Center Hamburg Eppendorf, Hamburg, Germany
J Magn Reson Imaging 32:1104-9. 2010..To assess regional iron distribution by magnetic resonance imaging (MRI)-R(2)* within the heart of patients with β-thalassemia major (TM) and other iron overload diseases...
- Impact of reduction of therapy on infectious complications in childhood acute lymphoblastic leukemiaUlrike B Graubner
University Children s Hospital, Department of Hematology and Oncology, Munich, Germany
Pediatr Blood Cancer 50:259-63. 2008..Infections are a major cause of morbidity and mortality in childhood acute lymphoblastic leukemia (ALL) and only limited information is available on infectious complications...